Figure 5 | Scientific Reports

Figure 5

From: Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer

Figure 5

BI2536 and nocodazole synergistically impair the viability of advanced PCa cells. DU145 cells (a) and normal epithelial prostate RWPE-1 cells (c) and were treated for 72 h with BI2536 or NoC, alone or in combination of indicated concentrations. Cell viability was assessed as in Fig. 4. (b) Combination index (CI) for BI2536 and NoC treatment of DU145 cells were calculated using the Calcusyn program.

Back to article page